单重与重复分析的实质性可比性 - - 一个生物相似PK研究中的临床免疫性后期评估
Maike Lichtenfels1, Jamie Fan2, Davide Guerrieri1
1Clinical Bioanalytics, Hexal AG (a Sandoz Company), HEXAL AG, Industriestr. 25, 83607, Holzkirchen, Germany.
The AAPS journal
|December 17, 2025
概括
在生物类似研究中,使用单个测试 (单基质) 进行免疫性测试是可行的. 这种方法保持了测试有效性和临床结果,同时减少了大约40%的分析工作量.
科学领域:
- 生物制药学分析
- 免疫学 免疫学 免疫学
- 测试开发 测试开发
背景情况:
- 免疫性测试对于生物类似药物的安全性和有效性至关重要.
- 传统的测试通常使用重复或三重复测量,增加工作量和成本.
- 评估基于单酸盐的测试的可行性对于优化生物类似药的开发至关重要.
研究的目的:
- 评估基于单酸盐的方法在生物类似环境中对抗药抗体 (ADA) 免疫性测定的可行性.
- 为了比较已建立的ADA试验和生物类似研究中的单重和重复数据.
- 确定单酸盐分析对试验验证和临床结果的影响.
主要方法:
- 使用单元数据重新计算了查,确认和标位切断点.
- 基于单元数据的重新评估的ADA方法验证参数.
- 进行了差异组件分析,以评估井到井的变性.
- 重新评估使用单位值的临床免疫性研究数据.
主要成果:
- 在重复和单重评估中,ADA试验验证参数是可比的.
- 差异组件分析表明,井到井变量的影响微不足道.
- 单位分析不会改变临床研究的免疫性结果.
- 一种基于单元的方法可以减少大约40%的分析工作量.
结论:
- 基于单酸盐的方法是可行的,可靠的免疫原性测试在生物类似的发展.
- 实施单项数据可以显著提高效率并降低成本,而不会损害数据完整性.
- 这一策略为优化生物模拟分析工作流提供了一个实用的解决方案.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
217
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
217
Bioequivalence Data: Statistical Interpretation
181
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
181
Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141
Bioavailability Study Design: Single Versus Multiple Dose Studies
179
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
179
Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
Equivalence: In Vitro and In Vivo Bioequivalence
193
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
193


